SCHEMBL6202380

SCHEMBL6202380

O=c1[nH]cnc2oc(-c3ccc(Cl)nc3)c(-c3ccccc3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TNK2 Q07912 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
AURKA O14965 3/20 0.39
DYRK1A Q13627 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
CHEK1 O14757 1/20 0.37
KDM4E B2RXH2 1/20 0.37
UBE2N P61088 1/20 0.37
KDR P35968 2/20 0.36
TEK Q02763 1/20 0.36
GSK3B P49841 1/20 0.36
SRC P12931 1/20 0.36
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
HSD17B10 Q99714 2/20 0.36
TSHR P16473 1/20 0.36
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6200056 0.89 RAB9A (0.40) RAB9ACHEK1GSK3BKCNQ3KCNQ2
SCHEMBL737611 0.86 TNK2 (0.52) NPC1RAB9ATNK2SMN1; SMN2AURKA
SCHEMBL14923117 0.83 AURKA (0.48) NPC1RAB9ATNK2SMN1; SMN2AURKA
SCHEMBL6200114 0.81 LMNA (0.47) NPC1RAB9ATNK2SMN1; SMN2AURKA
SCHEMBL6198726 0.81 PDPK1 (0.50) NPC1RAB9ATNK2SMN1; SMN2AURKA
SCHEMBL1786338 0.79 KDM4E (0.61) TNK2SMN1; SMN2AURKAALDH1A1HPGD
SCHEMBL1785591 0.79 TNK2 (0.43) NPC1RAB9ATNK2SMN1; SMN2AURKA
SCHEMBL6203015 0.78 KDR (0.43) NPC1RAB9ATNK2SMN1; SMN2AURKA
SCHEMBL6202574 0.78 TNK2 (0.53) NPC1RAB9ATNK2SMN1; SMN2AURKA
SCHEMBL12677063 0.75 AKT1 (0.44) TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1425283-B1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2005-03-16 EP disclosed
US-20040259888-A1 Novel 4-aminofuropyrimidines and the use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-23 US disclosed
EP-1425283-A1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF Bayer HealthCare AG (DE) 2004-06-09 EP disclosed
WO-2003018589-A1 NOVEL 4-AMINOFUROPYRIMIDINES AND THE USE THEREOF BAYER HEALTHCARE AG (DE) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259888-A1 Novel 4-aminofuropyrimidines and the use thereof DPYD, TPMT, TYMP NPC1 1312/4885RAB9A 3777/4885TNK2 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.